LeMaitre Vascular Inc (NASDAQ:LMAT) – Analysts at Barrington Research boosted their Q1 2018 earnings per share (EPS) estimates for LeMaitre Vascular in a research note issued on Thursday. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings of $0.20 per share for the quarter, up from their prior forecast of $0.19. Barrington Research also issued estimates for LeMaitre Vascular’s Q2 2018 earnings at $0.26 EPS, Q3 2018 earnings at $0.25 EPS and FY2018 earnings at $0.98 EPS.
A number of other analysts also recently weighed in on the company. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Tuesday, October 31st. BidaskClub downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Saturday, December 2nd. Finally, Canaccord Genuity reiterated a “hold” rating and set a $33.00 price target on shares of LeMaitre Vascular in a report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $34.00.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The business had revenue of $26.15 million during the quarter, compared to analyst estimates of $26.23 million. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. LeMaitre Vascular’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $0.13 EPS.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 5th. Shareholders of record on Thursday, March 22nd will be issued a dividend of $0.07 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. This represents a $0.28 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Wednesday, March 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 25.58%.
Institutional investors have recently modified their holdings of the business. Teachers Retirement System of The State of Kentucky acquired a new stake in LeMaitre Vascular during the 2nd quarter worth about $137,000. Victory Capital Management Inc. grew its holdings in LeMaitre Vascular by 181.2% during the 3rd quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after acquiring an additional 2,667 shares during the period. Royal Bank of Canada grew its holdings in LeMaitre Vascular by 856.5% during the 2nd quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 4,505 shares during the period. BB&T Corp acquired a new stake in LeMaitre Vascular during the 4th quarter worth about $202,000. Finally, Voya Investment Management LLC acquired a new stake in LeMaitre Vascular during the 2nd quarter worth about $203,000. Hedge funds and other institutional investors own 75.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Barrington Research Weighs in on LeMaitre Vascular Inc’s Q1 2018 Earnings (LMAT)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3227481/barrington-research-weighs-in-on-lemaitre-vascular-incs-q1-2018-earnings-lmat.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.